{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:15:31Z","timestamp":1788909331948,"version":"build-2803163510"},"reference-count":72,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:p>Therapy-induced senescence (TIS) is a potential outcome of anti-cancer treatments, characterized by a stable cell cycle arrest. However, it is now widely accepted that this process acts as a double-edged sword: in fact, senescent cells are active drivers of cancer relapse, aggressiveness and metastasis, through the release of pro-inflammatory factors and the ability to resume proliferation. Therefore, selectively targeting TIS cells, a strategy named one-two punch approach, is crucial to avoid their harmful effects. This may become particularly important for those aggressive tumors that currently lack effective therapeutic options, such as dedifferentiated thyroid tumors. To this purpose, identifying targetable characteristics of TIS cells is essential for the development of new senotherapeutics. TIS is often associated with variations of the autophagic flux, therefore, we investigated the interplay between autophagy and TIS in thyroid cancer cells, to explore a new potential target for senotherapy. We demonstrate that TIS thyroid cancer cells do not always exhibit a sufficient enlargement of the lysosomal compartment to maintain autophagy function. The deficiency in lysosomal biogenesis is driven by the inability of TFEB, the master regulator of this process, to properly enter and remain inside the nucleus. The disruption of the autophagic flux leads to the accumulation of SQSTM1\/p62, which in turn activates the Nrf2 pathway. In contrast to cells with functional autophagy, Nrf2-activated cells display a higher tolerance to oxidative stress, making them resistant to the senolytic activity of lysosomal inhibitors.<\/jats:p>","DOI":"10.1530\/erc-25-0291","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:14:01Z","timestamp":1768835641000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":1,"title":["Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells"],"prefix":"10.1530","volume":"33","author":[{"given":"Beatrice","family":"Mazzoleni","sequence":"first","affiliation":[{"name":"Integrated Biology of Rare Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Mazzoni","sequence":"additional","affiliation":[{"name":"Integrated Biology of Rare Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Vergaro","sequence":"additional","affiliation":[{"name":"Integrated Biology of Rare Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Di Marco","sequence":"additional","affiliation":[{"name":"Integrated Biology of Rare Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Pagliardini","sequence":"additional","affiliation":[{"name":"Integrated Biology of Rare Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2994-0349","authenticated-orcid":true,"given":"Angela","family":"Greco","sequence":"additional","affiliation":[{"name":"Integrated Biology of Rare Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Mech Ageing Dev","article-title":"Oncogene-induced senescence: from biology to therapy","volume":"187","author":"Zhu H","year":"2020","unstructured":"Zhu H\n, \nBlake S\n, \nKusuma FK\n, et al.\n Oncogene-induced senescence: from biology to therapy. Mech Ageing Dev 2020 187 111229. (https:\/\/doi.org\/10.1016\/j.mad.2020.111229)"},{"key":"bib2","series-title":"Nat Rev Cancer","first-page":"340","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang L","year":"2022","unstructured":"Wang L\n, \nLankhorst L\n & \nBernards R\n\n. Exploiting senescence for the treatment of cancer. Nat Rev Cancer 2022 22 340\u2013355. (https:\/\/doi.org\/10.1038\/s41568-022-00450-9)"},{"key":"bib3","series-title":"Trends Cell Biol","first-page":"436","article-title":"Hallmarks of cellular senescence","volume":"28","author":"Hernandez-Segura A","year":"2018","unstructured":"Hernandez-Segura A\n, \nNehme J\n & \nDemaria M\n\n. Hallmarks of cellular senescence. Trends Cell Biol 2018 28 436\u2013453. (https:\/\/doi.org\/10.1016\/j.tcb.2018.02.001)"},{"key":"bib4","series-title":"Nat Rev Nephrol","first-page":"611","article-title":"Cellular senescence: the good, the bad and the unknown","volume":"18","author":"Huang W","year":"2022","unstructured":"Huang W\n, \nHickson LJ\n, \nEirin A\n, et al.\n Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol 2022 18 611\u2013627. (https:\/\/doi.org\/10.1038\/s41581-022-00601-z)"},{"key":"bib5","series-title":"Nature","first-page":"96","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic M","year":"2018","unstructured":"Milanovic M\n, \nFan DNY\n, \nBelenki D\n, et al.\n Senescence-associated reprogramming promotes cancer stemness. Nature 2018 553 96\u2013100. (https:\/\/doi.org\/10.1038\/nature25167)"},{"key":"bib6","series-title":"Mol Oncol","first-page":"3855","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset L","year":"2022","unstructured":"Bousset L\n & \nGil J\n\n. Targeting senescence as an anticancer therapy. Mol Oncol 2022 16 3855\u20133880. (https:\/\/doi.org\/10.1002\/1878-0261.13312)"},{"key":"bib7","series-title":"Nat Commun","first-page":"2177","article-title":"Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer","volume":"13","author":"Troiani M","year":"2022","unstructured":"Troiani M\n, \nColucci M\n, \nD\u2019Ambrosio M\n, et al.\n Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun 2022 13 2177. (https:\/\/doi.org\/10.1038\/s41467-022-29824-1)"},{"key":"bib8","series-title":"EMBO J","first-page":"1921","article-title":"Pharmacological CDK4\/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer","volume":"44","author":"Nehme J","year":"2025","unstructured":"Nehme J\n, \nMaassen S\n, \nBravaccini S\n, et al.\n Pharmacological CDK4\/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer. EMBO J 2025 44 1921\u20131942. (https:\/\/doi.org\/10.1038\/s44318-025-00371-x)"},{"key":"bib9","series-title":"Endocrinol Metab Clin North Am","first-page":"391","article-title":"Anaplastic thyroid cancer: new horizons and challenges","volume":"51","author":"Maniakas A","year":"2022","unstructured":"Maniakas A\n, \nZafereo M\n & \nCabanillas ME\n\n. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am 2022 51 391\u2013401. (https:\/\/doi.org\/10.1016\/j.ecl.2021.11.020)"},{"key":"bib10","series-title":"JAMA","first-page":"425","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai L","year":"2024","unstructured":"Boucai L\n, \nZafereo M\n & \nCabanillas ME\n\n. Thyroid cancer: a review. JAMA 2024 331 425\u2013435. (https:\/\/doi.org\/10.1001\/jama.2023.26348)"},{"key":"bib11","series-title":"Cancers","first-page":"1061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin A","year":"2022","unstructured":"Jannin A\n, \nEscande A\n, \nAl Ghuzlan A\n, et al.\n Anaplastic thyroid carcinoma: an update. Cancers 2022 14 1061. (https:\/\/doi.org\/10.3390\/cancers14041061)"},{"key":"bib12","series-title":"Radiat Oncol Lond Engl","first-page":"10","article-title":"Radiation-induced senescence: therapeutic opportunities","volume":"18","author":"Kim JH","year":"2023","unstructured":"Kim JH\n, \nBrown SL\n & \nGordon MN\n\n. Radiation-induced senescence: therapeutic opportunities. Radiat Oncol Lond Engl 2023 18 10. (https:\/\/doi.org\/10.1186\/s13014-022-02184-2)"},{"key":"bib13","series-title":"Cancer Res","first-page":"5935","article-title":"Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence","volume":"81","author":"Fletcher-Sananikone E","year":"2021","unstructured":"Fletcher-Sananikone E\n, \nKanji S\n, \nTomimatsu N\n, et al.\n Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res 2021 81 5935\u20135947. (https:\/\/doi.org\/10.1158\/0008-5472.can-21-0752)"},{"key":"bib14","series-title":"EMBO J","article-title":"TFEB-dependent lysosome biogenesis is required for senescence","volume":"42","author":"Curnock R","year":"2023","unstructured":"Curnock R\n, \nYalci K\n, \nPalmfeldt J\n, et al.\n TFEB-dependent lysosome biogenesis is required for senescence. EMBO J 2023 42 e111241. (https:\/\/doi.org\/10.15252\/embj.2022111241)"},{"key":"bib15","series-title":"Aging Cell","article-title":"Ouabain and chloroquine trigger senolysis of BRAF\u2010V600E\u2010induced senescent cells by targeting autophagy","volume":"20","author":"L\u2019H\u00f4te V","year":"2021","unstructured":"L\u2019H\u00f4te V\n, \nCourbeyrette R\n, \nPinna G\n, et al.\n Ouabain and chloroquine trigger senolysis of BRAF\u2010V600E\u2010induced senescent cells by targeting autophagy. Aging Cell 2021 20 e13447. (https:\/\/doi.org\/10.1111\/acel.13447)"},{"key":"bib16","series-title":"Oncotarget","first-page":"34629","article-title":"Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening","volume":"6","author":"Anania MC","year":"2015","unstructured":"Anania MC\n, \nGasparri F\n, \nCetti E\n, et al.\n Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening. Oncotarget 2015 6 34629\u201334648. (https:\/\/doi.org\/10.18632\/oncotarget.5282)"},{"key":"bib17","series-title":"Int J Mol Sci","first-page":"5744","article-title":"BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells","volume":"22","author":"Bonaldi E","year":"2021","unstructured":"Bonaldi E\n, \nGargiuli C\n, \nDe Cecco L\n, et al.\n BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells. Int J Mol Sci 2021 22 5744. (https:\/\/doi.org\/10.3390\/ijms22115744)"},{"key":"bib18","series-title":"Bio Protoc","article-title":"In vitro tumorsphere formation assays","volume":"3","author":"Johnson S","year":"2013","unstructured":"Johnson S\n, \nChen H\n & \nLo PK\n\n. In vitro tumorsphere formation assays. Bio Protoc 2013 3 e325. (https:\/\/doi.org\/10.21769\/bioprotoc.325)"},{"key":"bib19","series-title":"Mol Oncol","first-page":"3259","article-title":"Autophagy at the intersection of aging, senescence, and cancer","volume":"16","author":"Cassidy LD","year":"2022","unstructured":"Cassidy LD\n & \nNarita M\n\n. Autophagy at the intersection of aging, senescence, and cancer. Mol Oncol 2022 16 3259\u20133275. (https:\/\/doi.org\/10.1002\/1878-0261.13269)"},{"key":"bib20","series-title":"EMBO Rep","article-title":"Lysosomes in senescence and aging","volume":"24","author":"Tan JX","year":"2023","unstructured":"Tan JX\n & \nFinkel T\n\n. Lysosomes in senescence and aging. EMBO Rep 2023 24 e57265. (https:\/\/doi.org\/10.15252\/embr.202357265)"},{"key":"bib21","series-title":"J Cell Sci","first-page":"2475","article-title":"TFEB at a glance","volume":"129","author":"Napolitano G","year":"2016","unstructured":"Napolitano G\n & \nBallabio A\n\n. TFEB at a glance. J Cell Sci 2016 129 2475\u20132481. (https:\/\/doi.org\/10.1242\/jcs.146365)"},{"key":"bib22","series-title":"Nat Commun","first-page":"1693","article-title":"Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance","volume":"10","author":"Li S","year":"2019","unstructured":"Li S\n, \nSong Y\n, \nQuach C\n, et al.\n Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun 2019 10 1693. (https:\/\/doi.org\/10.1038\/s41467-019-09634-8)"},{"key":"bib23","series-title":"Cell Rep","first-page":"1915","article-title":"Nuclear export inhibition enhances HLH-30\/TFEB activity, autophagy, and lifespan","volume":"23","author":"Silvestrini MJ","year":"2018","unstructured":"Silvestrini MJ\n, \nJohnson JR\n, \nKumar AV\n, et al.\n Nuclear export inhibition enhances HLH-30\/TFEB activity, autophagy, and lifespan. Cell Rep 2018 23 1915\u20131921. (https:\/\/doi.org\/10.1016\/j.celrep.2018.04.063)"},{"key":"bib24","series-title":"Apoptosis Int J Program Cell Death","first-page":"1191","article-title":"Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress","volume":"21","author":"Masud Alam M","year":"2016","unstructured":"Masud Alam M\n, \nKariya R\n, \nKawaguchi A\n, et al.\n Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress. Apoptosis Int J Program Cell Death 2016 21 1191\u20131201. (https:\/\/doi.org\/10.1007\/s10495-016-1277-7)"},{"key":"bib25","series-title":"Endocr Relat Cancer","first-page":"431","article-title":"Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress","volume":"27","author":"Nakano K","year":"2020","unstructured":"Nakano K\n, \nMasui T\n, \nYogo A\n, et al.\n Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress. Endocr Relat Cancer 2020 27 431\u2013439. (https:\/\/doi.org\/10.1530\/erc-20-0028)"},{"key":"bib26","series-title":"FEBS J","first-page":"4672","article-title":"p62\/SQSTM1 functions as a signaling hub and an autophagy adaptor","volume":"282","author":"Katsuragi Y","year":"2015","unstructured":"Katsuragi Y\n, \nIchimura Y\n & \nKomatsu M\n\n. p62\/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J 2015 282 4672\u20134678. (https:\/\/doi.org\/10.1111\/febs.13540)"},{"key":"bib27","series-title":"EMBO J","article-title":"The complex relationship between TFEB transcription factor phosphorylation and subcellular localization","volume":"37","author":"Puertollano R","year":"2018","unstructured":"Puertollano R\n, \nFerguson SM\n, \nBrugarolas J\n, et al.\n The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J 2018 37 e98804. (https:\/\/doi.org\/10.15252\/embj.201798804)"},{"key":"bib28","series-title":"J Hematol Oncolj Hematol Oncol","first-page":"61","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian NG","year":"2020","unstructured":"Azizian NG\n & \nLi Y\n\n. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncolj Hematol Oncol 2020 13 61. (https:\/\/doi.org\/10.1186\/s13045-020-00903-4)"},{"key":"bib29","series-title":"J Endocrinol","first-page":"R43","article-title":"Key signaling pathways in thyroid cancer","volume":"235","author":"Zaballos MA","year":"2017","unstructured":"Zaballos MA\n & \nSantisteban P\n\n. Key signaling pathways in thyroid cancer. J Endocrinol 2017 235 R43\u2013R61. (https:\/\/doi.org\/10.1530\/joe-17-0266)"},{"key":"bib30","series-title":"Sci Rep","first-page":"9749","article-title":"Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin","volume":"7","author":"Garg M","year":"2017","unstructured":"Garg M\n, \nKanojia D\n, \nMayakonda A\n, et al.\n Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci Rep 2017 7 9749. (https:\/\/doi.org\/10.1038\/s41598-017-10325-x)"},{"key":"bib31","series-title":"Transl Cancer Res","first-page":"4664","article-title":"Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis","volume":"10","author":"Zhao L","year":"2021","unstructured":"Zhao L\n, \nLuo B\n, \nWang L\n, et al.\n Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis. Transl Cancer Res 2021 10 4664\u20134679. (https:\/\/doi.org\/10.21037\/tcr-21-1646)"},{"key":"bib32","series-title":"Theranostics","first-page":"681","article-title":"NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the ATR-CHK1 signaling pathway","volume":"14","author":"Sun X","year":"2024","unstructured":"Sun X\n, \nDong M\n, \nLi J\n, et al.\n NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the ATR-CHK1 signaling pathway. Theranostics 2024 14 681\u2013698. (https:\/\/doi.org\/10.7150\/thno.88899)"},{"key":"bib33","series-title":"Biomed Pharmacother Biomedecine Pharmacother","article-title":"Targeting Nrf2 to treat thyroid cancer","volume":"173","author":"Gong Z","year":"2024","unstructured":"Gong Z\n, \nXue L\n, \nLi H\n, et al.\n Targeting Nrf2 to treat thyroid cancer. Biomed Pharmacother Biomedecine Pharmacother 2024 173 116324. (https:\/\/doi.org\/10.1016\/j.biopha.2024.116324)"},{"key":"bib34","series-title":"Curr Opin Immunol","first-page":"98","article-title":"The host targeting effect of chloroquine in malaria","volume":"66","author":"Coban C","year":"2020","unstructured":"Coban C\n\n. The host targeting effect of chloroquine in malaria. Curr Opin Immunol 2020 66 98\u2013107. (https:\/\/doi.org\/10.1016\/j.coi.2020.07.005)"},{"key":"bib35","series-title":"EMBO Mol Med","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk EL","year":"2020","unstructured":"Nirk EL\n, \nReggiori F\n & \nMauthe M\n\n. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med 2020 12 e12476. (https:\/\/doi.org\/10.15252\/emmm.202012476)"},{"key":"bib36","series-title":"Int J Nanomedicine","first-page":"6777","article-title":"Pharmacology progresses and applications of chloroquine in cancer therapy","volume":"19","author":"Liu Y","year":"2024","unstructured":"Liu Y\n, \nMeng Y\n, \nZhang J\n, et al.\n Pharmacology progresses and applications of chloroquine in cancer therapy. Int J Nanomedicine 2024 19 6777\u20136809. (https:\/\/doi.org\/10.2147\/ijn.s458910)"},{"key":"bib1","series-title":"Mech Ageing Dev","article-title":"Oncogene-induced senescence: from biology to therapy","volume":"187","author":"Zhu H","year":"2020","unstructured":"Zhu H\n, \nBlake S\n, \nKusuma FK\n, et al.\n Oncogene-induced senescence: from biology to therapy. Mech Ageing Dev 2020 187 111229. (https:\/\/doi.org\/10.1016\/j.mad.2020.111229)"},{"key":"bib2","series-title":"Nat Rev Cancer","first-page":"340","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang L","year":"2022","unstructured":"Wang L\n, \nLankhorst L\n & \nBernards R\n\n. Exploiting senescence for the treatment of cancer. Nat Rev Cancer 2022 22 340\u2013355. (https:\/\/doi.org\/10.1038\/s41568-022-00450-9)"},{"key":"bib3","series-title":"Trends Cell Biol","first-page":"436","article-title":"Hallmarks of cellular senescence","volume":"28","author":"Hernandez-Segura A","year":"2018","unstructured":"Hernandez-Segura A\n, \nNehme J\n & \nDemaria M\n\n. Hallmarks of cellular senescence. Trends Cell Biol 2018 28 436\u2013453. (https:\/\/doi.org\/10.1016\/j.tcb.2018.02.001)"},{"key":"bib4","series-title":"Nat Rev Nephrol","first-page":"611","article-title":"Cellular senescence: the good, the bad and the unknown","volume":"18","author":"Huang W","year":"2022","unstructured":"Huang W\n, \nHickson LJ\n, \nEirin A\n, et al.\n Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol 2022 18 611\u2013627. (https:\/\/doi.org\/10.1038\/s41581-022-00601-z)"},{"key":"bib5","series-title":"Nature","first-page":"96","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic M","year":"2018","unstructured":"Milanovic M\n, \nFan DNY\n, \nBelenki D\n, et al.\n Senescence-associated reprogramming promotes cancer stemness. Nature 2018 553 96\u2013100. (https:\/\/doi.org\/10.1038\/nature25167)"},{"key":"bib6","series-title":"Mol Oncol","first-page":"3855","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset L","year":"2022","unstructured":"Bousset L\n & \nGil J\n\n. Targeting senescence as an anticancer therapy. Mol Oncol 2022 16 3855\u20133880. (https:\/\/doi.org\/10.1002\/1878-0261.13312)"},{"key":"bib7","series-title":"Nat Commun","first-page":"2177","article-title":"Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer","volume":"13","author":"Troiani M","year":"2022","unstructured":"Troiani M\n, \nColucci M\n, \nD\u2019Ambrosio M\n, et al.\n Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun 2022 13 2177. (https:\/\/doi.org\/10.1038\/s41467-022-29824-1)"},{"key":"bib8","series-title":"EMBO J","first-page":"1921","article-title":"Pharmacological CDK4\/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer","volume":"44","author":"Nehme J","year":"2025","unstructured":"Nehme J\n, \nMaassen S\n, \nBravaccini S\n, et al.\n Pharmacological CDK4\/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer. EMBO J 2025 44 1921\u20131942. (https:\/\/doi.org\/10.1038\/s44318-025-00371-x)"},{"key":"bib9","series-title":"Endocrinol Metab Clin North Am","first-page":"391","article-title":"Anaplastic thyroid cancer: new horizons and challenges","volume":"51","author":"Maniakas A","year":"2022","unstructured":"Maniakas A\n, \nZafereo M\n & \nCabanillas ME\n\n. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am 2022 51 391\u2013401. (https:\/\/doi.org\/10.1016\/j.ecl.2021.11.020)"},{"key":"bib10","series-title":"JAMA","first-page":"425","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai L","year":"2024","unstructured":"Boucai L\n, \nZafereo M\n & \nCabanillas ME\n\n. Thyroid cancer: a review. JAMA 2024 331 425\u2013435. (https:\/\/doi.org\/10.1001\/jama.2023.26348)"},{"key":"bib11","series-title":"Cancers","first-page":"1061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin A","year":"2022","unstructured":"Jannin A\n, \nEscande A\n, \nAl Ghuzlan A\n, et al.\n Anaplastic thyroid carcinoma: an update. Cancers 2022 14 1061. (https:\/\/doi.org\/10.3390\/cancers14041061)"},{"key":"bib12","series-title":"Radiat Oncol Lond Engl","first-page":"10","article-title":"Radiation-induced senescence: therapeutic opportunities","volume":"18","author":"Kim JH","year":"2023","unstructured":"Kim JH\n, \nBrown SL\n & \nGordon MN\n\n. Radiation-induced senescence: therapeutic opportunities. Radiat Oncol Lond Engl 2023 18 10. (https:\/\/doi.org\/10.1186\/s13014-022-02184-2)"},{"key":"bib13","series-title":"Cancer Res","first-page":"5935","article-title":"Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence","volume":"81","author":"Fletcher-Sananikone E","year":"2021","unstructured":"Fletcher-Sananikone E\n, \nKanji S\n, \nTomimatsu N\n, et al.\n Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res 2021 81 5935\u20135947. (https:\/\/doi.org\/10.1158\/0008-5472.can-21-0752)"},{"key":"bib14","series-title":"EMBO J","article-title":"TFEB-dependent lysosome biogenesis is required for senescence","volume":"42","author":"Curnock R","year":"2023","unstructured":"Curnock R\n, \nYalci K\n, \nPalmfeldt J\n, et al.\n TFEB-dependent lysosome biogenesis is required for senescence. EMBO J 2023 42 e111241. (https:\/\/doi.org\/10.15252\/embj.2022111241)"},{"key":"bib15","series-title":"Aging Cell","article-title":"Ouabain and chloroquine trigger senolysis of BRAF\u2010V600E\u2010induced senescent cells by targeting autophagy","volume":"20","author":"L\u2019H\u00f4te V","year":"2021","unstructured":"L\u2019H\u00f4te V\n, \nCourbeyrette R\n, \nPinna G\n, et al.\n Ouabain and chloroquine trigger senolysis of BRAF\u2010V600E\u2010induced senescent cells by targeting autophagy. Aging Cell 2021 20 e13447. (https:\/\/doi.org\/10.1111\/acel.13447)"},{"key":"bib16","series-title":"Oncotarget","first-page":"34629","article-title":"Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening","volume":"6","author":"Anania MC","year":"2015","unstructured":"Anania MC\n, \nGasparri F\n, \nCetti E\n, et al.\n Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening. Oncotarget 2015 6 34629\u201334648. (https:\/\/doi.org\/10.18632\/oncotarget.5282)"},{"key":"bib17","series-title":"Int J Mol Sci","first-page":"5744","article-title":"BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells","volume":"22","author":"Bonaldi E","year":"2021","unstructured":"Bonaldi E\n, \nGargiuli C\n, \nDe Cecco L\n, et al.\n BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells. Int J Mol Sci 2021 22 5744. (https:\/\/doi.org\/10.3390\/ijms22115744)"},{"key":"bib18","series-title":"Bio Protoc","article-title":"In vitro tumorsphere formation assays","volume":"3","author":"Johnson S","year":"2013","unstructured":"Johnson S\n, \nChen H\n & \nLo PK\n\n. In vitro tumorsphere formation assays. Bio Protoc 2013 3 e325. (https:\/\/doi.org\/10.21769\/bioprotoc.325)"},{"key":"bib19","series-title":"Mol Oncol","first-page":"3259","article-title":"Autophagy at the intersection of aging, senescence, and cancer","volume":"16","author":"Cassidy LD","year":"2022","unstructured":"Cassidy LD\n & \nNarita M\n\n. Autophagy at the intersection of aging, senescence, and cancer. Mol Oncol 2022 16 3259\u20133275. (https:\/\/doi.org\/10.1002\/1878-0261.13269)"},{"key":"bib20","series-title":"EMBO Rep","article-title":"Lysosomes in senescence and aging","volume":"24","author":"Tan JX","year":"2023","unstructured":"Tan JX\n & \nFinkel T\n\n. Lysosomes in senescence and aging. EMBO Rep 2023 24 e57265. (https:\/\/doi.org\/10.15252\/embr.202357265)"},{"key":"bib21","series-title":"J Cell Sci","first-page":"2475","article-title":"TFEB at a glance","volume":"129","author":"Napolitano G","year":"2016","unstructured":"Napolitano G\n & \nBallabio A\n\n. TFEB at a glance. J Cell Sci 2016 129 2475\u20132481. (https:\/\/doi.org\/10.1242\/jcs.146365)"},{"key":"bib22","series-title":"Nat Commun","first-page":"1693","article-title":"Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance","volume":"10","author":"Li S","year":"2019","unstructured":"Li S\n, \nSong Y\n, \nQuach C\n, et al.\n Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun 2019 10 1693. (https:\/\/doi.org\/10.1038\/s41467-019-09634-8)"},{"key":"bib23","series-title":"Cell Rep","first-page":"1915","article-title":"Nuclear export inhibition enhances HLH-30\/TFEB activity, autophagy, and lifespan","volume":"23","author":"Silvestrini MJ","year":"2018","unstructured":"Silvestrini MJ\n, \nJohnson JR\n, \nKumar AV\n, et al.\n Nuclear export inhibition enhances HLH-30\/TFEB activity, autophagy, and lifespan. Cell Rep 2018 23 1915\u20131921. (https:\/\/doi.org\/10.1016\/j.celrep.2018.04.063)"},{"key":"bib24","series-title":"Apoptosis Int J Program Cell Death","first-page":"1191","article-title":"Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress","volume":"21","author":"Masud Alam M","year":"2016","unstructured":"Masud Alam M\n, \nKariya R\n, \nKawaguchi A\n, et al.\n Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress. Apoptosis Int J Program Cell Death 2016 21 1191\u20131201. (https:\/\/doi.org\/10.1007\/s10495-016-1277-7)"},{"key":"bib25","series-title":"Endocr Relat Cancer","first-page":"431","article-title":"Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress","volume":"27","author":"Nakano K","year":"2020","unstructured":"Nakano K\n, \nMasui T\n, \nYogo A\n, et al.\n Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress. Endocr Relat Cancer 2020 27 431\u2013439. (https:\/\/doi.org\/10.1530\/erc-20-0028)"},{"key":"bib26","series-title":"FEBS J","first-page":"4672","article-title":"p62\/SQSTM1 functions as a signaling hub and an autophagy adaptor","volume":"282","author":"Katsuragi Y","year":"2015","unstructured":"Katsuragi Y\n, \nIchimura Y\n & \nKomatsu M\n\n. p62\/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J 2015 282 4672\u20134678. (https:\/\/doi.org\/10.1111\/febs.13540)"},{"key":"bib27","series-title":"EMBO J","article-title":"The complex relationship between TFEB transcription factor phosphorylation and subcellular localization","volume":"37","author":"Puertollano R","year":"2018","unstructured":"Puertollano R\n, \nFerguson SM\n, \nBrugarolas J\n, et al.\n The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J 2018 37 e98804. (https:\/\/doi.org\/10.15252\/embj.201798804)"},{"key":"bib28","series-title":"J Hematol Oncolj Hematol Oncol","first-page":"61","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian NG","year":"2020","unstructured":"Azizian NG\n & \nLi Y\n\n. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncolj Hematol Oncol 2020 13 61. (https:\/\/doi.org\/10.1186\/s13045-020-00903-4)"},{"key":"bib29","series-title":"J Endocrinol","first-page":"R43","article-title":"Key signaling pathways in thyroid cancer","volume":"235","author":"Zaballos MA","year":"2017","unstructured":"Zaballos MA\n & \nSantisteban P\n\n. Key signaling pathways in thyroid cancer. J Endocrinol 2017 235 R43\u2013R61. (https:\/\/doi.org\/10.1530\/joe-17-0266)"},{"key":"bib30","series-title":"Sci Rep","first-page":"9749","article-title":"Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin","volume":"7","author":"Garg M","year":"2017","unstructured":"Garg M\n, \nKanojia D\n, \nMayakonda A\n, et al.\n Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci Rep 2017 7 9749. (https:\/\/doi.org\/10.1038\/s41598-017-10325-x)"},{"key":"bib31","series-title":"Transl Cancer Res","first-page":"4664","article-title":"Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis","volume":"10","author":"Zhao L","year":"2021","unstructured":"Zhao L\n, \nLuo B\n, \nWang L\n, et al.\n Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis. Transl Cancer Res 2021 10 4664\u20134679. (https:\/\/doi.org\/10.21037\/tcr-21-1646)"},{"key":"bib32","series-title":"Theranostics","first-page":"681","article-title":"NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the ATR-CHK1 signaling pathway","volume":"14","author":"Sun X","year":"2024","unstructured":"Sun X\n, \nDong M\n, \nLi J\n, et al.\n NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the ATR-CHK1 signaling pathway. Theranostics 2024 14 681\u2013698. (https:\/\/doi.org\/10.7150\/thno.88899)"},{"key":"bib33","series-title":"Biomed Pharmacother Biomedecine Pharmacother","article-title":"Targeting Nrf2 to treat thyroid cancer","volume":"173","author":"Gong Z","year":"2024","unstructured":"Gong Z\n, \nXue L\n, \nLi H\n, et al.\n Targeting Nrf2 to treat thyroid cancer. Biomed Pharmacother Biomedecine Pharmacother 2024 173 116324. (https:\/\/doi.org\/10.1016\/j.biopha.2024.116324)"},{"key":"bib34","series-title":"Curr Opin Immunol","first-page":"98","article-title":"The host targeting effect of chloroquine in malaria","volume":"66","author":"Coban C","year":"2020","unstructured":"Coban C\n\n. The host targeting effect of chloroquine in malaria. Curr Opin Immunol 2020 66 98\u2013107. (https:\/\/doi.org\/10.1016\/j.coi.2020.07.005)"},{"key":"bib35","series-title":"EMBO Mol Med","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk EL","year":"2020","unstructured":"Nirk EL\n, \nReggiori F\n & \nMauthe M\n\n. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med 2020 12 e12476. (https:\/\/doi.org\/10.15252\/emmm.202012476)"},{"key":"bib36","series-title":"Int J Nanomedicine","first-page":"6777","article-title":"Pharmacology progresses and applications of chloroquine in cancer therapy","volume":"19","author":"Liu Y","year":"2024","unstructured":"Liu Y\n, \nMeng Y\n, \nZhang J\n, et al.\n Pharmacology progresses and applications of chloroquine in cancer therapy. Int J Nanomedicine 2024 19 6777\u20136809. (https:\/\/doi.org\/10.2147\/ijn.s458910)"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/2\/ERC-25-0291.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/2\/ERC-25-0291.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/2\/ERC-25-0291.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:12:34Z","timestamp":1772129554000},"score":1,"resource":{"primary":{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/2\/ERC-25-0291.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":72,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0291","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]}}}